Bristol-Myers Flags Early Success for PhIII Opdivo Study in Kidney Cancer

Monday, July 20, 2015

Source: FierceBiotech

Bristol-Myers Squibb ($BMY) flagged an early success for its Phase III Opdivo (nivolumab) study for kidney cancer, saying that an independent monitoring group concluded that its closely watched checkpoint inhibitor has beat Afinitor (everolimus) in improving overall survival for advanced patients.

View All News »